Blocking LIF and PD-L1 enhances the antitumor efficacy of SBRT in murine PDAC models
Background
Recent preclinical and clinical data suggest that leukemia inhibitory factor (LIF) is a potential target for various tumor types including pancreatic ductal adenocarcinoma as LIF is involved in multiple protumor processes including cancer s…